镥[177Lu]奥曲肽对恶性胰岛素瘤相关严重难治性低血糖的长期影响。
LONG-TERM EFFECT OF LU-DOTATATE ON SEVERE AND REFRACTORY HYPOGLYCEMIA ASSOCIATED WITH MALIGNANT INSULINOMA.
作者信息
Iglesias Pedro, Martínez Alberto, Gajate Pablo, Alonso Teresa, Navarro Teresa, Díez Juan J
出版信息
AACE Clin Case Rep. 2019 Jun 26;5(6):e330-e333. doi: 10.4158/ACCR-2019-0086. eCollection 2019 Nov-Dec.
Abstract
OBJECTIVE
Malignant insulinoma is an extremely uncommon tumor that is usually accompanied by severe hypoglycemia that is difficult to manage. At this time, the long-term effect of Lu-DOTATATE (lutetium [Lu-177]-DOTA-Tyr3-octreotate) on this tumor is not well known.
METHODS
We report a case of severe, life-threatening, and refractory hypoglycemia associated with malignant insulinoma treated with Lu-DOTATATE.
RESULTS
A 51-year-old woman was referred because of severe, life-threatening, and refractory hypoglycemia due to malignant insulinoma. The patient had been treated unsuccessfully with chemotherapy, targeted therapies, and symptomatic therapy with diazoxide, steroids, and somatostatin analogues without success. Lu-DOTATATE adequately controlled her hypoglycemia after the other conventional treatments failed.
CONCLUSION
Lu-DOTATATE was effective in providing rapid and long-term symptomatic control of the hypoglycemia and significantly improved the quality of life of the patient.
摘要
目的
恶性胰岛素瘤是一种极为罕见的肿瘤，通常伴有难以控制的严重低血糖。目前，镥-多他肽（镥[Lu-177]-多他肽-酪氨酰3-奥曲肽）对该肿瘤的长期疗效尚不清楚。
方法
我们报告一例用镥-多他肽治疗的与恶性胰岛素瘤相关的严重、危及生命且难治性低血糖病例。
结果
一名51岁女性因恶性胰岛素瘤导致严重、危及生命且难治性低血糖前来就诊。该患者接受化疗、靶向治疗以及用二氮嗪、类固醇和生长抑素类似物进行对症治疗均未成功。在其他常规治疗失败后，镥-多他肽充分控制了她的低血糖。
结论
镥-多他肽能有效快速且长期地对症控制低血糖，并显著改善患者的生活质量。
相似文献
1
LONG-TERM EFFECT OF LU-DOTATATE ON SEVERE AND REFRACTORY HYPOGLYCEMIA ASSOCIATED WITH MALIGNANT INSULINOMA.镥[177Lu]奥曲肽对恶性胰岛素瘤相关严重难治性低血糖的长期影响。
AACE Clin Case Rep. 2019 Jun 26;5(6):e330-e333. doi: 10.4158/ACCR-2019-0086. eCollection 2019 Nov-Dec.
2
Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE.病例报告：177Lu-DOTATATE 成功治疗胰岛素依赖型 2 型糖尿病转移性胰岛素瘤引起的低血糖
Front Endocrinol (Lausanne). 2022 May 24;13:906012. doi: 10.3389/fendo.2022.906012. eCollection 2022.
4
High clinical and morphologic response using Y-DOTA-octreotate sequenced with Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.使用钇-多胺-奥曲肽与镥-多胺-奥曲肽诱导肽受体化学放射性核素疗法（PRCRT）序贯治疗巨大神经内分泌肿瘤时具有较高的临床和形态学反应。
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):476-489. doi: 10.1007/s00259-016-3527-x. Epub 2016 Sep 27.
5
Lutetium-labelled peptides for therapy of neuroendocrine tumours.镥标记的肽用于神经内分泌肿瘤的治疗。
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12. doi: 10.1007/s00259-011-2039-y.
6
Ga-DOTATATE PET/CT imaging in endogenous hyperinsulinemic hypoglycemia: A tertiary endocrine centre experience.镓- DOTATATE PET/CT 成像在自发性胰岛素瘤性低血糖症中的应用：一个三级内分泌中心的经验。
Clin Endocrinol (Oxf). 2022 Feb;96(2):190-199. doi: 10.1111/cen.14586. Epub 2021 Sep 8.
7
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.长效放射性标记生长抑素类似物 Lu-DOTA-EB-TATE 在晚期转移性神经内分泌肿瘤患者中的安全性、药代动力学和剂量学。
J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13.
8
The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols.用（177）镥-奥曲肽肽受体放射性核素治疗副神经节瘤患者的挑战：儿茶酚胺危象、肿瘤溶解综合征以及治疗方案修改的必要性
Nucl Med Mol Imaging. 2015 Sep;49(3):223-30. doi: 10.1007/s13139-015-0332-6. Epub 2015 Apr 9.
9
Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.两例无法手术的恶性胰岛素瘤患者持续性低血糖的医学治疗。
Eur J Endocrinol. 2010 May;162(5):1001-8. doi: 10.1530/EJE-09-1010. Epub 2010 Feb 17.
10
Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?[（177）Lu-DOTA（0），Tyr（3）]奥曲肽与[（177）Lu-DOTA（0），Tyr（3）]奥曲肽的比较：哪种肽更适合肽受体放射性核素治疗？
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51. doi: 10.1007/s00259-006-0172-9. Epub 2006 Jul 18.
引用本文的文献
1
History of an Insidious Case of Metastatic Insulinoma.一例隐匿性转移性胰岛素瘤的病史
J Clin Med. 2025 Jun 6;14(12):4028. doi: 10.3390/jcm14124028.
2
Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.胰岛素瘤患者低血糖的管理——三级中心经验及文献综述
Clin Endocrinol (Oxf). 2025 Mar;102(3):344-354. doi: 10.1111/cen.15188. Epub 2024 Dec 30.
3
Hypoglycemia in a Non-diabetic Patient and the Side Effects of Diazoxide Use.非糖尿病患者的低血糖症及二氮嗪使用的副作用
Cureus. 2023 Mar 28;15(3):e36804. doi: 10.7759/cureus.36804. eCollection 2023 Mar.
4
Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE.病例报告：177Lu-DOTATATE 成功治疗胰岛素依赖型 2 型糖尿病转移性胰岛素瘤引起的低血糖
Front Endocrinol (Lausanne). 2022 May 24;13:906012. doi: 10.3389/fendo.2022.906012. eCollection 2022.
5
Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.功能性神经内分泌肿瘤综合征治疗的当前药物治疗策略展望。
Expert Opin Pharmacother. 2021 Apr;22(6):685-693. doi: 10.1080/14656566.2020.1845651. Epub 2020 Nov 11.
本文引用的文献
1
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
2
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.ENETS关于肠道、胰腺、支气管神经内分泌肿瘤（NEN）及原发部位不明的NEN远处转移疾病管理的共识指南更新
Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5.
3
Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.转移性胰岛素瘤胰腺神经内分泌肿瘤经 177Lu-DOTATATE 诱导和维持肽受体放射性核素治疗：建议方案。
Clin Nucl Med. 2016 Jan;41(1):53-4. doi: 10.1097/RLU.0000000000001023.
4
Management of endocrine disease: a clinical update on tumor-induced hypoglycemia.内分泌疾病的管理：肿瘤诱导性低血糖的临床最新进展。
Eur J Endocrinol. 2014 Mar 14;170(4):R147-57. doi: 10.1530/EJE-13-1012. Print 2014 Apr.
5
Metastatic insulinoma managed with radiolabeled somatostatin analog.采用放射性标记生长抑素类似物治疗转移性胰岛素瘤。
Case Rep Endocrinol. 2013;2013:252159. doi: 10.1155/2013/252159. Epub 2013 Dec 17.
6
Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy.通过肽受体放射性核素治疗改善恶性胰岛素瘤患者严重低血糖的控制。
J Clin Endocrinol Metab. 2011 Nov;96(11):3381-9. doi: 10.1210/jc.2011-1563. Epub 2011 Sep 14.
7
Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.两例无法手术的恶性胰岛素瘤患者持续性低血糖的医学治疗。
Eur J Endocrinol. 2010 May;162(5):1001-8. doi: 10.1530/EJE-09-1010. Epub 2010 Feb 17.
8
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.用放射性标记的生长抑素类似物[177 Lu-DOTA 0，Tyr3]奥曲肽进行治疗：毒性、疗效和生存期。
J Clin Oncol. 2008 May 1;26(13):2124-30. doi: 10.1200/JCO.2007.15.2553.
9
Recurrent hyperinsulinemic hypoglycemia caused by an insulin-secreting insulinoma.由分泌胰岛素的胰岛素瘤引起的复发性高胰岛素血症性低血糖症。
Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):467-70; quiz following 470. doi: 10.1038/ncpendmet0263.
Zotero 插件